# Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy

> **NCT07091370** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Juventas Cell Therapy Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- AIHA - Cold Autoimmune Hemolytic Anemia

## Interventions

- **DRUG:** Inaticabtagene Autoleucel Injection

## Key facts

- **NCT ID:** NCT07091370
- **Lead sponsor:** Juventas Cell Therapy Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-27
- **Primary completion:** 2026-09-30
- **Final completion:** 2028-03-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07091370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07091370, "Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07091370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*